FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
What happened
FDA inspected Stream2Sea's drug manufacturing facility in Bowling Green, FL, from July 9 to 15, 2025. Investigators found the firm released OTC drug batches without testing the finished product for identity, strength, quality or purity, and one batch was released before the quality unit documented release approval. FDA also found no identity testing of incoming raw materials including active ingredients, reliance on supplier certificates of analysis without qualifying suppliers, and cleaning of shared drug and cosmetics equipment that was neither validated nor properly documented.
What FDA found
The firm did not test each finished drug batch for identity and strength of active ingredients, or for other quality attributes, before releasing it.
21 CFR 211.165(a)The firm did not test incoming raw materials and components, including active ingredients, to confirm their identity, and did not qualify suppliers or verify that supplier test results were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not validate its cleaning procedures to remove drug residue and cleaning agents or control microbes on equipment shared between OTC drugs and cosmetics, and did not document what cleaning was done.
21 CFR 211.67(b)
What FDA wants
FDA tells the firm to fix the violations promptly and to respond in writing within 15 working days with corrective actions, or explain any delay and give a completion schedule. The letter also asks for independent reviews of the laboratory, material and cleaning systems, and strongly recommends hiring a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drug products from this contract manufacturer
- companies sharing drug and cosmetic manufacturing equipment
- quality teams that rely on supplier certificates of analysis instead of identity testing
This is a summary. Read the original letter on fda.gov.